Targets in myeloma are interesting and hopeful for our futures as bispecific antibodies continue to become a key treatment option. Using the immune system to fight multiple myeloma makes great sense...
The Changing of the Targets
read more
Michael Tuohy
Michael Tuohy was diagnosed with multiple myeloma in 2000 when he was 36 years old. With two young children (ages 2 and 7) the focus was always on finding the best treatment options, and beating myeloma. He had an autologous stem cell transplant in 2002, and is currently on Revlimid® His approach over the years has been to become empowered by learning as much as he could to have productive conversations with his doctors, and to then share his experience with others to help them along their own journey. He and his wife Robin started the first myeloma support group in Connecticut in the Spring of 2001 with the help of the IMF, which is known as the Connecticut Multiple Myeloma Fighters Information Group.
Follow Michael on Twitter: @IMFmikeMYELOMA
Support Group Website: Connecticut Multiple Myeloma Fighters Information Group
Lower / No Dex!
I appreciate that there are abstracts that are looking for data regarding lower / no dex. Dr. Mikhael paints a great picture of how dex could be used like a rocket booster on a spaceship. When the...
If Only I Had a Crystal Ball
As we prepare for ASH 2022, I’m honored to be a part of this dedicated team of patients and support group leaders and grateful to the International Myeloma Foundation for continuing to educationally...